Show simple item record

dc.contributor.authorChakravarthy, A
dc.contributor.authorFurness, A
dc.contributor.authorJoshi, K
dc.contributor.authorGhorani, E
dc.contributor.authorFord, K
dc.contributor.authorWard, MJ
dc.contributor.authorKing, EV
dc.contributor.authorLechner, M
dc.contributor.authorMarafioti, T
dc.contributor.authorQuezada, SA
dc.contributor.authorThomas, GJ
dc.contributor.authorFeber, A
dc.contributor.authorFenton, TR
dc.date.accessioned2020-08-25T15:41:34Z
dc.date.issued2018-08-13
dc.identifier.citationNature communications, 2018, 9 (1), pp. 3220 - ?
dc.identifier.issn2041-1723
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4005
dc.identifier.eissn2041-1723
dc.identifier.doi10.1038/s41467-018-05570-1
dc.description.abstractThe nature and extent of immune cell infiltration into solid tumours are key determinants of therapeutic response. Here, using a DNA methylation-based approach to tumour cell fraction deconvolution, we report the integrated analysis of tumour composition and genomics across a wide spectrum of solid cancers. Initially studying head and neck squamous cell carcinoma, we identify two distinct tumour subgroups: 'immune hot' and 'immune cold', which display differing prognosis, mutation burden, cytokine signalling, cytolytic activity and oncogenic driver events. We demonstrate the existence of such tumour subgroups pan-cancer, link clonal-neoantigen burden to cytotoxic T-lymphocyte infiltration, and show that transcriptional signatures of hot tumours are selectively engaged in immunotherapy responders. We also find that treatment-naive hot tumours are markedly enriched for known immune-resistance genomic alterations, potentially explaining the heterogeneity of immunotherapy response and prognosis seen within this group. Finally, we define a catalogue of mediators of active antitumour immunity, deriving candidate biomarkers and potential targets for precision immunotherapy.
dc.formatElectronic
dc.format.extent3220 - ?
dc.languageeng
dc.language.isoeng
dc.publisherNATURE PUBLISHING GROUP
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectTh1 Cells
dc.subjectCell Line, Tumor
dc.subjectMacrophages
dc.subjectHumans
dc.subjectPapillomaviridae
dc.subjectProteome
dc.subjectReproducibility of Results
dc.subjectCell Cycle
dc.subjectDNA Methylation
dc.subjectMutation
dc.subjectGenome, Human
dc.subjectTranscriptome
dc.subjectSquamous Cell Carcinoma of Head and Neck
dc.titlePan-cancer deconvolution of tumour composition using DNA methylation.
dc.typeJournal Article
dcterms.dateAccepted2018-07-10
rioxxterms.versionofrecord10.1038/s41467-018-05570-1
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-08-13
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfNature communications
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume9
pubs.embargo.termsNot known
dc.contributor.icrauthorFurness, Andrew
dc.contributor.icrauthorFeber, Andrew


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0